|
30 参阅孙浩琛.论TRIPS协议和公共健康[J].当代法学研究（沪）.2002第4期.
31 前引F. M. Schere & Jayashree Watal, P913文中摘要部分认为。
32 TRIPS协议第30条“所授权利之例外”规定：成员可对所授的专有权规定有限的例外，只要在顾及第三方合法利益的前提下，该例外并未与专利的正常利用不合理地冲突，也并未不合理地损害专利所有人的合法利益。
33 Peter J. Hammer, Differential Pricing of Essential AIDS Drugs: Markets, Politics and Public Health, Journal of International Economic Law, p906。
34 参见前引Peter J. Hammer文， P908。
35 前引Peter J. Hammer文。
36 前引F. M. Schere & Jayashree Watal文, P913。
37 比如，Patricia M. Danzon写了很多文章力陈差别定价有能力创造更多的更有效的R&D刺激。See Patricia M. Danzon, Pharmaceutical Price Regulation: National Policies Versus Global Interests, 11-13(1997);Patricia M. Danzon, Differential Pricing: Reconciling R &D, Intellectual Property and Access, WHO-WTO Hosbjor Conference, 2001.
38 比如以下文章： Herry Grabowski, Patents, Innovation and Access to New Pharmaceuticals, JIEL, vol.5, no 4, Dec. 2002, pp857和前引F. M. Schere & Jayashree Watal文中即都大力提倡捐赠作为一种解决途径。
39 F. M. Schere & Jayashree Watal, Post-TRIPS Options for Access to Patented Medicines in Developing Nations, CMH Working Paper Series, Paper No. WG4 : 1, available at: www.cmhhealth.org/cmh_papers&reports.htm.
40 可以参见:http://www.wto.org/english/tratop_e/trips_e/factsheet_pharm03_e.htm
41 前引F. M. Schere & Jayashree Watal一文便这样认为。
42 Jacques Bourgai & Thaddeus Burns, Transferable Marketing Exclusivity: An Incentive for Development of Medicines for the Developing and Least Developed World, European Business Law Review, vol.12, Issue11/12, 2001, pp 286-281
43 所谓的罕见病，根据美国相关法律的规定，是指仅仅感染200，000例以下病人的疾病或医学条件。参阅Sheila R. Schulman, et, Implementation of The Orphan Drugs Act: 1983-1991, 47, Food and Drug Law Journal, 1992, pp363-403.
44Herry Grabowski, Patents, Innovation and Access to New Pharmaceuticals, JIEL, vol.5, no 4, Dec. 2002, pp849-860:
45参阅吕炳斌.基因科技发展对法律的挑战.科技与法律[J].2002（1）.或法理学、法史学（人大报刊复印资料）[J].2002（12），等。
46比如第8条规定：.成员可在其国内法律及条例的制定或修订中，采取必要措施以保护公众的健康与发展，以增加对其社会经济与技术发展至关紧要之领域中的公益，只要该措施与本协议的规定一致。
47“Opening Address by Mr. Brian Burdekin”, Intellectual Property and Human Rights, Geneva, World Intellectual Property Organization and the Office of the United Nations High Commissioner for Human Rights,1999, WIPO Publication No.726(E), P8
48冯洁涵."全球公共健康危机、知识产权国际保护与WTO多哈宣言".法学评论(武汉)[J].2003年4月第2期.
49Intellectual Property and Human Rights,Geneva, World Intellectual Property Organization and the Office of the United Nations High Commissioner for Human Rights,1999, WIPO Publication No.726(E)
50Sub-Commission for the Promotion and Protection of Human Rights, resolution 2000/7 and resolution 2001/21
51Human Rights and Intellectual Property Issues: Statement by the Committee on Economic, Social and Cultural Rights, E/C.12/2001/15,26 Nov. 2001
52Andrey R. Chapman, The Human Right Implications of Intellectual Property Protection, Journal of International Economic Law, p868
53余涛.多哈宣言、人权宣言、权利层级.中国知识产权报[N].2002-11-04
54Andrew R. Chapman, The Human Right Implications of Intellectual Property Protection, Journal of International Economic Law, p881.
--------------
主要参考文献：
[英文文献为不完全收录，中文根据武汉大学法学院网站提供的法学论文检索目录（其目录包括了一些市级新闻出版机关批准的连续性法学刊物的文章），可能这些文章已经代表了国内已有的相关研究成果，检索时间段为2001年年底至今]
|
